Home » Stocks » FGEN

FibroGen, Inc. (FGEN)

Stock Price: $40.02 USD -1.31 (-3.17%)
Updated November 25, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 3.64B
Revenue (ttm) 119.30M
Net Income (ttm) -228.78M
Shares Out 91.01M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $40.02
Previous Close $41.33
Change ($) -1.31
Change (%) -3.17%
Day's Open 41.33
Day's Range 39.84 - 41.70
Day's Volume 377,663
52-Week Range 22.65 - 51.56

More Stats

Market Cap 3.64B
Enterprise Value 3.00B
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 91.01M
Float 83.23M
EPS (basic) -2.61
EPS (diluted) -2.57
FCF / Share 0.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.11%
Payout Ratio n/a
Shares Short 8.06M
Short Ratio 13.37
Short % of Float 9.68%
Beta 1.70
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 90.07
PS Ratio 30.53
PB Ratio 8.16
Revenue 119.30M
Operating Income -234.32M
Net Income -228.78M
Free Cash Flow 40.44M
Net Cash 646.20M
Net Cash / Share 7.10
Gross Margin 38.70%
Operating Margin -196.42%
Profit Margin -191.80%
FCF Margin 33.90%
ROA -17.17%
ROE -42.19%
ROIC -47.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 4
Overweight 0
Hold 4
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(66.34% upside)
Current: $40.02
Target: 66.57
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth20.48%62.57%-28.49%1.31%31.41%34.68%54.96%-
Gross Profit25521313118318113810265.93
Operating Income-89.31-86.69-117-50.04-77.63-50.10-7.95-27.22
Net Income-76.97-86.42-121-58.07-85.78-59.50-14.94-32.57
Shares Outstanding86.6384.0672.9962.7460.3418.7813.1913.13
Earnings Per Share-0.89-1.03-1.66-0.93-1.42-3.17-1.13-2.48
Operating Cash Flow-78.71-76.14-66.517.11-18.5722.4125.92-5.61
Capital Expenditures-5.76-7.84-8.50-1.25-1.98-8.11-6.80-0.74
Free Cash Flow-84.46-83.98-75.015.86-20.5514.3119.11-6.35
Cash & Equivalents53462173625318118713047.14
Total Debt51.1097.1697.7697.3597.0496.8296.8193.23
Net Cash / Debt48352463815684.1390.2633.25-46.09
Book Value516509528156178221-88.71-73.95
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name FibroGen, Inc.
Country United States
Employees 531
CEO Enrique A. Conterno

Stock Information

Ticker Symbol FGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FGEN
IPO Date November 14, 2014


FibroGen, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.